NRAS and melanoma: Indeed, in melanoma other oncogenic driver mutations mediate tumorigenesis via activation of MAPK/ERK signaling, including activating NRAS mutations and loss-of function mutations in NF1, a GTPase known to downregulate RAS activity (28).